RE:RE:RE:AstraZeneca's ADC disappoints - on severe adverse eventsLast year, Roche’s breast cancer ADC Kadcyla topped the ADC leaderboard with $3 billion in sales.
An Evaluate generated report calls the antibody-drug conjugate (ADC) market the “hottest real estate in oncology” that will continue to attract big pharma investment over the next few years. In 2023, ADC-focused M&A and partnership activity totaled almost $100 billion in total in 2023, more than three times the value of similar deals in 2022 and nine times more than in 2019.
At the same time, he said there are significant challenges for the sector given that the design of ADCs is not as “predictable” as initially thought and that there is still trial and error involved in their development.
https://www.biospace.com/article/adc-market-will-remain-hot-in-oncology-reaching-30b-by-2028-report/